Rhonda Wideman

2003 Research Trainee Award, Master's

Effect of glucagon-like peptide-1 on islet transplantation

More than two million Canadians and 135 million people worldwide have diabetes, a chronic medical condition characterized by a lack of insulin to regulate blood sugar levels (Type 1), or insensitivity to insulin (Type 2). Transplanting islets, the cells in the pancreas that produce insulin, can cure Type 1 diabetes. But use of this therapy is limited because of the huge volume of islet tissue required to treat all Type 1 diabetics. As a result, most continue to rely on insulin injections to help control blood glucose. Glucagon-like peptide-1 (GLP-1) is produced in the intestine and has numerous anti-diabetic effects. Clinical trials are currently investigating GLP-1 as a treatment for Type 2 diabetes. Other recent studies show GLP-1 also enhances the growth of islet tissue. Rhonda Wideman is investigating the effects of GLP-1 on the growth and survival of transplanted islets to determine if GLP-1 reduces the amount of islets needed to cure Type 1 diabetes in transplant recipients. If so, more islet tissue could be produced and more patients could be treated with this procedure. Completed award term, March 2005 Received 2005 MSFHR Trainee Award
Read Rhonda Wideman's 2005 Trainee profile

Back to 2003 Research Trainee Awards